PT92509A - Process for the preparation of neutrophil-activating peptide-2 - Google Patents

Process for the preparation of neutrophil-activating peptide-2 Download PDF

Info

Publication number
PT92509A
PT92509A PT92509A PT9250989A PT92509A PT 92509 A PT92509 A PT 92509A PT 92509 A PT92509 A PT 92509A PT 9250989 A PT9250989 A PT 9250989A PT 92509 A PT92509 A PT 92509A
Authority
PT
Portugal
Prior art keywords
leu
ala
ile
ser
arg
Prior art date
Application number
PT92509A
Other languages
English (en)
Inventor
Marco Baggiolini
Kenneth John Clemetson
Alfred Walz
Original Assignee
Sandoz Sa
Kocher Theodor Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB888828728A external-priority patent/GB8828728D0/en
Priority claimed from GB898909681A external-priority patent/GB8909681D0/en
Application filed by Sandoz Sa, Kocher Theodor Inst filed Critical Sandoz Sa
Publication of PT92509A publication Critical patent/PT92509A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/522—Alpha-chemokines, e.g. NAP-2, ENA-78, GRO-alpha/MGSA/NAP-3, GRO-beta/MIP-2alpha, GRO-gamma/MIP-2beta, IP-10, GCP-2, MIG, PBSF, PF-4, KC
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5421—IL-8
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Claims (7)

  1. R E ΓΤ IHPIOAQOBS ia. _ Processo para a preparação do péptido-2 acti-vador dos nautrófilofl (NSA-l/IAP-2) ou de um variante, um fragmento ou um derivado funcional do citado péptido-2, ca-racterizado pelo facto de compreender a purificação de leucócitos do sangue estimulados a partir de líquidos de cultura, mediante cromatografia em fosfocelulose e cromatogra- ! fia em fase inversa.
  2. 2^. - Processo de acordo com a reivindicação 1, ca-racterizado pelo facto de compreender a) a cromatografia em fosfocelulose, b) a cromatografia em fase' líquida inversa sob alta pressão, numa coluna 04, e c) a cromatografia em fase líquida inversa, sob alta pressão, numa coluna de OET-propilo.
  3. 3§. - Processo para a preparação de NSA-l/MAP-2 ou de um seu variante fragmento ou derivado funcionais, ou de uma sua estrutura relativa biologicamente activa, tal como -^-tromboglobilina (beta-TG·), péptido de activação do tecido conectivo III (CTAP-III (CTAP-III ou proteina básica de plaquetas (PEP) caracterizado pelo facto de compreender a clo-nação de um gene correspondente, que inclui uma sequência principal natural, a expressão do gene num hospedeiro adequa do e a recuperação, de forma apropriada, do péptido assim produzido, se for conveniente, através da utilização de uma protease apropriada.
  4. 4§. - Processo de acordo com a reivindicação 3> caracterizado pelo facto de a sequência principal codificar: 1 5
    10 MET-Ser-Ieu-Arg-leu-Asp-Thr-Thr-Pro-Ser-11 15 20 Cys-Asn-Ser-Ala-Arg-Pro-leu-His-Ala-Ieu-21 25 30 Gln-Val-Ieu-Leu-Ieu-leu-Ser-leu-Ieu-Leu-31 Thr-Ala-Ieu-Ala- ou um variante, um fragmento ou um derivado funcionais da referida sequência.
  5. 5-· - Processo de acordo com qualquer das reivin dicações 1 a 4, caracterizado pelo facto de se preparar o factor que tem a seguinte sequência de 70 aminoácidos 1 5 10 Ala-Glu-leu-Arg-Cys-Met-Cys-Ile-lys-Tlir-11 15 20 Thr-Ser-Gly-Ile-His-Pro-Lys-Asn-Ile-Gln-21 25 30 Ser-Ieu-Glu-Val-Ile-Gly-lys-Gly-Thr-His-31 35 40 Cys-Asn-Gin-Vai-Glu-Val-Ile-Ala-Thr-Ieu-41 45 50 Lys-Asp-Gly-Arg-lys-Ile-Cys-Ijeu-Asp-Pro-51 55 ' 60 Asp-Ala-Pro-Arg-Ile-lys-Iys-Ile-Val-Gln-61 65 70 lys -Iiys -le u-Ala- Gly-Asp- Glu-Ser-Ala-As p ou de um variante fragmento ou derivado funcionais da citada sequência.
  6. 6§. - Processo para a preparação do factor de acti-vação de neutrófilos ou de um seu variante, fragmento ou derivado, de acordo com a reivindicação 1, caracterizado pelo facto de a sua obtenção se fazer a partir de beta-IG-, CIAP--III ou PEP ou de um gene codificado com beta-TG·, CTAP-III ou PBP.
  7. 7-· - Processo para a preparação de um péptido prin cipal, caracterizado pelo facto de possuir a seguinte seçjuên cia de aminoáeidos: 15 10 MET-Ser-Ieu-Arg-Ieu-Asp-Tbr-Ihr-Pro-Ser-11 15 20 Cys-Asn-Ser-Ala-Arg-Pro-leu-His-Ala-Ieu-21 25 30 Gln-Val-Ieu-Leu-Ieu-leu-Ser-leu-Ieu-leu-31 Thr-Ala-leu-Ala- ou um variante, um fragmento ou um derivado funcionais, da mencionada sequência. Lisboa, 6 de Dezembro de 1989 0 Agente Oficial da Propriedade Industrial
    Américo da Silva Carvalho Agente Oficial de Propriedade industrial R. Castilho, 201-3. £.-1000 LiSBOA Telefs. Ó5 13 39-65 46 13
PT92509A 1988-12-08 1989-12-06 Process for the preparation of neutrophil-activating peptide-2 PT92509A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB888828728A GB8828728D0 (en) 1988-12-08 1988-12-08 Neutrophil-stimulating activity i
GB898909681A GB8909681D0 (en) 1989-04-27 1989-04-27 Neutrophil-stimulating activity 1

Publications (1)

Publication Number Publication Date
PT92509A true PT92509A (pt) 1990-06-29

Family

ID=26294713

Family Applications (1)

Application Number Title Priority Date Filing Date
PT92509A PT92509A (pt) 1988-12-08 1989-12-06 Process for the preparation of neutrophil-activating peptide-2

Country Status (19)

Country Link
US (1) US5759533A (pt)
JP (1) JP3051160B2 (pt)
KR (1) KR910700260A (pt)
AU (1) AU634508B2 (pt)
BE (1) BE1003636A4 (pt)
CA (1) CA2004685A1 (pt)
CH (1) CH681625A5 (pt)
DK (1) DK188690A (pt)
ES (1) ES2047458A6 (pt)
FI (1) FI903931A0 (pt)
FR (1) FR2640142B1 (pt)
GB (1) GB2231872B (pt)
GR (1) GR1000455B (pt)
IL (1) IL92557A0 (pt)
NL (1) NL8921262A (pt)
NZ (1) NZ231652A (pt)
PT (1) PT92509A (pt)
SE (1) SE9002589D0 (pt)
WO (1) WO1990006321A1 (pt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH681625A5 (pt) * 1988-12-08 1993-04-30 Sandoz Ag
US6673893B1 (en) * 1990-02-01 2004-01-06 University Of South Florida Leukocyte derived growth factor 2
WO1991011515A2 (en) * 1990-02-01 1991-08-08 University Of South Florida Leukocyte-derived growth factor
AU2348492A (en) * 1991-07-19 1993-02-23 East Carolina University Method of treating asthma
WO1993009794A1 (en) * 1991-11-15 1993-05-27 University Of Pennsylvania Suppression of megakaryocytopoiesis by neutrophil activating peptide-2
AU6085694A (en) * 1993-01-07 1994-08-15 University Of South Florida Leukocyte derived growth factors
US5578569A (en) * 1993-03-12 1996-11-26 Tam; Cherk S. Method of increasing bone growth
US5786327A (en) 1993-03-12 1998-07-28 Gensci Regeneration Sciences Inc. Bone stimulating factor, methods of isolating same, and methods of increasing bone growth comprising administering same
US6458349B1 (en) 1995-06-02 2002-10-01 Human Genome Sciences, Inc. Chemokine β-4 polypeptides
US6391589B1 (en) 1994-08-23 2002-05-21 Human Genome Sciences, Inc. Human chemokine beta-10 mutant polypeptides
US6174995B1 (en) 1994-08-23 2001-01-16 Haodong Li Human chemokines, CKβ4 and CKβ10/MCP-4
US5912232A (en) * 1994-09-23 1999-06-15 Board Of Regents Of The University Of Nebraska Anti-inflammatory polypeptide antagonists of human I1-8
US6352973B1 (en) 1995-06-07 2002-03-05 Osteopharm Inc. Bone stimulating factor
US5880094A (en) * 1995-06-07 1999-03-09 Osteopharm Limited Polypeptides that stimulate bone growth
US6117839A (en) * 1995-06-07 2000-09-12 Gensci Regeneration Sciences, Inc. Bone stimulating factor
US6693081B2 (en) * 1995-09-26 2004-02-17 Osteopharm Inc. Bone stimulating factor
US6290948B1 (en) 1996-05-14 2001-09-18 Smithkline Beecham Corporation Method of treating sepsis and ARDS using chamohine beta-10
EP1015486A2 (en) 1997-09-25 2000-07-05 Academisch Ziekenhuis bij de Universiteit van Amsterdam Isolated and recombinant antimicrobial peptides thrombocidin-1 (tc-1) and thrombocidin-2 (tc-2) or variants thereof
GB9807721D0 (en) 1998-04-08 1998-06-10 Chiron Spa Antigen
EP2110436B1 (en) * 2000-03-07 2013-01-30 Japan Tobacco Inc. Polypeptides having neutrophil stimulating activity
US6815421B1 (en) 2001-03-22 2004-11-09 Osteopharm Inc. Polypeptides for use in ameliorating effects of aging in mammals
US7375192B2 (en) 2002-05-01 2008-05-20 Human Genome Sciences, Inc. Antibodies that specifically bind to chemokine beta-4
US7177246B2 (en) * 2003-09-12 2007-02-13 Hewlett-Packard Development Company, L.P. Optical disk drive focusing apparatus using sum signal
NZ611269A (en) 2010-11-19 2015-03-27 Eisai R&D Man Co Ltd Neutralizing anti-ccl20 antibodies
KR101993316B1 (ko) * 2017-04-11 2019-06-26 나민자 강아지 배변기
KR102453406B1 (ko) 2020-08-24 2022-10-11 연세흠 반려동물 배변수거기

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4897348A (en) * 1983-08-25 1990-01-30 Sri International Recombinant materials and methods for producing human connective tissue-activating peptide-III and analogs thereof
DE3737703A1 (de) * 1987-11-06 1989-05-18 Ferring Arzneimittel Gmbh Neutrophilen aktivierendes polypeptid, verfahren zu dessen herstellung sowie dessen verwendung als arzneimittel und diagnostikum
US5026639A (en) * 1988-01-14 1991-06-25 Nippon Mining Company, Limited Method to improve mRNA translation and use thereof for production of platelet factor-4
CH681625A5 (pt) * 1988-12-08 1993-04-30 Sandoz Ag

Also Published As

Publication number Publication date
JPH03503767A (ja) 1991-08-22
GR890100810A (en) 1991-03-15
KR910700260A (ko) 1991-03-14
GB2231872A (en) 1990-11-28
CA2004685A1 (en) 1990-06-08
AU634508B2 (en) 1993-02-25
BE1003636A4 (fr) 1992-05-12
CH681625A5 (pt) 1993-04-30
NL8921262A (nl) 1990-11-01
FR2640142A1 (fr) 1990-06-15
WO1990006321A1 (en) 1990-06-14
SE9002589L (sv) 1990-08-07
DK188690D0 (da) 1990-08-07
GB2231872B (en) 1992-07-22
GB9011468D0 (en) 1990-08-29
GR1000455B (el) 1992-07-30
AU4655689A (en) 1990-06-26
FR2640142B1 (fr) 1994-09-23
IL92557A0 (en) 1990-08-31
JP3051160B2 (ja) 2000-06-12
DK188690A (da) 1990-08-07
SE9002589D0 (sv) 1990-08-07
FI903931A0 (fi) 1990-08-08
NZ231652A (en) 1993-02-25
US5759533A (en) 1998-06-02
ES2047458A6 (es) 1994-02-16

Similar Documents

Publication Publication Date Title
PT92509A (pt) Process for the preparation of neutrophil-activating peptide-2
Proost et al. Human and bovine granulocyte chemotactic protein-2: complete amino acid sequence and functional characterization as chemokines
Davey et al. Hydrophobic interaction of human interferon with concanavalin A-agarose
Hemker et al. Nature of prothrombin biosynthesis: preprothrombinaemia in vitamin K-deficiency
KR890003802A (ko) 재조합 dna 기술에 의해 제조된 소의 췌장 트립신 억제제, 그 제조 방법, 발현 벡터 및 재조합 숙주 및 그의 제약적 용도
US4636489A (en) Modified protease inhibitors, process for their preparation, and pharmaceutical compositions prepared therefrom
AU660192B2 (en) Novel neutrophil activating factors
ZA90861B (en) Derivative of tissue-type plasminogen activator
WO1997049373A3 (en) Treatment and prevention of hiv infection by administration of derivatives of human chorionic gonadotropin
BR9205640A (pt) Dímero de apolipoproteína ai-milano, composiçao farmacológica, processo de preparaçao do dímero, uso deste na preparaçao de medicamentos e processo para o tratamento de aterosclerose e doenças cardiovasculares
EP0133767B1 (en) Gamma interferon composition
KR910000171A (ko) 헤멘테리아 길리아니 거머리로부터 항응고 물질을 추출 및 정제방법
Sulkowski et al. Interaction of human interferons with immobilized hydrophobic amino acids and dipeptides.
KR910009246A (ko) 폴리펩타이드를 함유하는 피하투여용 또는 근육내 투여용 약제
HK1007333A1 (en) Variants of plasminogen activatos and processes for their production
NZ264218A (en) Storage stable aqueous composition of alpha-interferon
ES2080060T3 (es) Proteinas que tienen actividad de union a interferon-gamma.
KR860006484A (ko) 단백질 또는 당단백질의 제조방법
EP0220966A3 (en) Purification method for proteins
KR930004326A (ko) 콘드로모듈린-ii 단백질
KR890017268A (ko) 항종양 활성을 갖는 단백질
KR860000869A (ko) γ-인터페론 안정화 조성물의 제조방법
Ken et al. Binding of amino α-lactam antibiotics to soluble protein from rat intestinal mucosa—I: Purification of drug-binding protein
Dempfle et al. Isolation and purification of fibrinogen/fibrin degradation products by chromatography on protamine-agarose
Jeng Hydrophobicity of neuraminidase-treated rabbit interferon

Legal Events

Date Code Title Description
FC3A Refusal

Effective date: 19951020